Browsing by Author "Arslan H."

Now showing 1 - 3 of 3
  • No Thumbnail Available
    Item
    Levels of serum trace elements in renal cell carcinoma case
    (Asian Pacific Organization for Cancer Prevention, 2013) Pirinççi N.; Geçit I.; Güneş M.; Kaba M.; Tanik S.; Yüksel M.B.; Arslan H.; Demir H.
    Trace elements which are essential components of biological structures may also be toxic when present at levels above the amounts required for biological function. In our study, traceelement levels were measured with furnace atomic absorption spectrophotometry in 33 newly diagnosed renal cell carcinoma cases (preoperative) and 32 healthy controls. When compared with the control group, it was found that the levels of cadmium (Cd), lead (Pb) were higher and the levels of zinc (Zn), iron (Fe) and manganese (Mn) were lower in the patient group.These changesmay be important in the formation of renal cell carcinoma, a question which should be exploredwith postoperative comparative studies.
  • No Thumbnail Available
    Item
    Comparison of clinical features of cystic fibrosis patients eligible but not on CFTR modulators to ineligible for CFTR modulators
    (John Wiley and Sons Inc, 2024) Nayır Büyükşahin H.; Emiralioğlu N.; Yalçın E.; Şen V.; Selimoğlu Şen H.; Arslan H.; Başkan A.K.; Çakır F.B.; Koray C.F.; Yılmaz A.İ.; Ercan F.; Altıntaş D.U.; Serbes M.; Keskin Ö.; Arık E.; Gülen F.; Barlık M.; Karcıoğlu O.; Damadoğlu E.; Köse M.; Ersoy A.; Bingöl A.; Başaran E.; Çakır E.P.; Aslan A.T.; Canıtez Y.; Korkmaz M.; Özdemir A.; Harmancı K.; Soydaş Ş.S.; Hangül M.; Yüksel H.; Özcan G.; Korkmaz P.; Kılıç M.; Gayretli Aydın Z.G.; Çaltepe G.; Can D.; Doğru S.; Kartal Öztürk G.; Süleyman A.; Topal E.; Özsezen B.; Hızal M.; Demirdöğen E.; Ogun H.; Börekçi Ş.; Yazan H.; Çakır E.; Şişmanlar Eyüboğlu T.; Çobanoğlu N.; Cinel G.; Pekcan S.; Özçelik U.; Doğru D.
    Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulator drugs target the underlying defect and improve CFTR function. They are a part of standard care in many countries, but not all patients are eligible for these drugs due to age and genotype. Here, we aimed to determine the characteristics of non-eligible patients for CFTR modulators in the CF registry of Turkey (CFRT) to highlight their clinical needs. Methods: This retrospective cohort study included CF patient data from the CFRT in 2021. The decision of eligibility for the CFTR modulator was determined according to the ‘Vertex treatment-Finder' on the Vertex® website. Demographic and clinical characteristics of patients were compared between eligible (group 1) and ineligible (group 2) groups for CFTR modulators. Results: Among the study population (N = 1527), 873 (57.2%) were in group 1 and 654 (42.8%) were in group 2. There was no statistical difference between groups regarding sex, meconium ileus history, diagnoses via newborn screening, FEV1 z-score, CF-associated complications, organ transplant history, and death. Patients in group 2 had a higher incidence of pancreatic insufficiency (87.7% vs. 83.2%, p =.010), lower median height z-scores (−0.87 vs. −0.55, p <.001), lower median body mass index z-scores (−0.65 vs. −0.50, p <.001), longer days receiving antibiotics due to pulmonary exacerbation (0 [interquartile range, IQR: 0–2] vs. 0 [IQR: 0–7], p = 0.001), and more non-invasive ventilation support (2.6% vs. 0.9%, p = 0.008) than patients in group 1. Conclusion: The ineligible group had worse clinical outcomes than the eligible group. This highlights their need for life-changing drugs to improve clinical outcomes. © 2024 Wiley Periodicals LLC.
  • No Thumbnail Available
    Item
    Comparison of refugee patients with cystic fibrosis and their counterpart children from Turkey during the war
    (Springer Science and Business Media Deutschland GmbH, 2024) Yılmaz A.İ.; Pekcan S.; Eyüboğlu T.Ş.; Hangül M.; Arslan H.; Kılınç A.A.; Çokuğraş H.; Arık E.; Keskin Ö.; Özdemir A.; Ersoy M.; Ersoy A.; Köse M.; Özsezen B.; Ünal G.; Ercan Ö.; Girit S.; Oksay S.C.; Gökdemir Y.; Karadağ B.; Şen V.; Çakır E.; Yüksel H.; Tekin M.N.; Aslan A.T.
    Since the outbreak of the Syrian civil war in 2011, the population of Arab refugees in Turkey has rapidly increased. While cystic fibrosis (CF) is believed to be rare among Arabs, recent studies suggest it is underdiagnosed. This study aims to present the demographic, clinical, and genetic characteristics of CF patients among Arab refugees in Turkey. Additionally, a comparison is made between the findings in the National CF Registry 2021 in Turkey (NCFRT) and the refugee CF patient group. The study included refugee patients between the ages of 0 and 18 years who were diagnosed with CF and received ongoing care at pediatric pulmonology centers from March 2011 to March 2021. The study examined demographic information, age at diagnosis, age of diagnosis of patients through CF newborn screening (NBS), presenting symptoms, CF transmembrane conductance regulator (CFTR) mutation test results, sputum culture results, weight, height, and body mass index (BMI) z score. Their results were compared with the NCFRT results. The study included 14 pediatric pulmonology centers and 87 patients, consisting of 46 (52.9%) boys and 41 (47.1%) girls. All of the patients were Arab refugees, with 80 (92%) being Syrian. All the patients were diagnosed in Turkey. The median age at diagnosis of patients was 22.33 (interquartile range, 1–258) months. The median age of diagnosis of patients through NBS was 4.2 (interquartile range, 1–12) months. The median age of older patients, who were unable to be included in the NBS program, was 32.3 (interquartile range, 3–258) months. Parental consanguinity was observed in 52 (59.7%) patients. The mutation that was most frequently found was F508del, which accounted for 22.2% of the cases. It was present in 20 patients, constituting 32 out of the total 144 alleles. There was a large number of genetic variations. CFTR genotyping could not be conducted for 12 patients. These patients had high sweat tests, and their genetic mutations could not be determined due to a lack of data. Compared to NCFRT, refugee patients were diagnosed later, and long-term follow-up of refugee CF patients had significantly worse nutritional status and pseudomonas colonization. Conclusion: Although refugee CF patients have equal access to NBS programs and CF medications as well as Turkish patients, the median age at diagnosis of patients, the median age of diagnosis of patients through NBS, their nutritional status, and Pseudomonas colonization were significantly worse than Turkish patients, which may be related to the difficulties of living in another country and poor living conditions. The high genetic heterogeneity and rare mutations detected in the refugee patient group compared to Turkish patients. Well-programmed NBS programs, thorough genetic studies, and the enhancement of living conditions for refugee patients in the countries they relocate to can have several advantages such as early detection and improved prognosis. (Table presented.) © The Author(s) 2024.